Financial Results of the Company, for the quarter 31-12-2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd filed its unaudited standalone and consolidated financial results for Q3 FY26 (quarter ended 31 Dec 2025), reviewed by Vasavi & Co with a clean limited review opinion. Revenue from operations stood at just ₹5.45 lakhs, down from ₹7.65 lakhs in the same quarter last year, and other income collapsed to zero versus ₹4.38 lakhs a year ago. The company posted a loss after tax of ₹37.38 lakhs for the quarter, widening sharply from a ₹8.90 lakh loss in Q3 FY25. For the nine months ended December 2025, the loss was ₹119.59 lakhs, compared to a marginal profit of ₹3.70 lakhs in the same period last year. The main damage came from a massive spike in finance costs (₹27.35 lakhs in Q3 vs ₹1.73 lakhs YoY) and the disappearance of other income (₹73.96 lakhs in 9M FY25 to nil in 9M FY26). The filing also flags ongoing legal proceedings at SAT (next hearing 24 Feb 2026), the Appellate Tribunal New Delhi (next hearing 14 Apr 2026), and NCLT Hyderabad (next hearing 3 Mar 2026).
For shareholders, the picture has deteriorated meaningfully: core revenue remains negligible, the company has swung from a small profit to a sizeable loss in nine months, and a 15-fold jump in finance costs signals growing debt pressure. Combined with multiple pending legal matters, this is a weak quarter with no near-term positive triggers visible from these numbers.